Skip to main content
  • genomeweb
  • 360dx
360Dx
  • RSS Feeds
  • Twitter
  • LinkedIn
  • Forgot your password?
  • Subscribe
  • Business & Policy
      • Business News
      • Research Funding
      • Policy & Legislation
      • Regulatory News
      • Reimbursement
  • Clinical Lab Management
  • Diagnostics
      • Molecular Diagnostics
      • Immunoassays
      • Tissue-Based Testing
      • Clinical Chemistry
      • Hematology/Coagulation
      • Point-of-Care Testing
      • Companion Diagnostics
  • Disease Areas
      • Cancer
      • Infectious Disease
      • Cardiovascular Disease
      • Neurological & Psychological Disease
      • Autoimmune Disease
      • Inherited Disease
      • Reproductive Health
      • Respiratory
      • Gastrointestinal
  • Resources
      • Webinars
      • White Papers
      • Job Listings
      • New Products
      • People in the News
      • Conferences & Events

Main menu

Home › Preterm Birth Risk, Preeclampsia Exosome Tests Enter Clinical Validation

Preterm Birth Risk, Preeclampsia Exosome Tests Enter Clinical Validation

Oct 24, 2018

NEW YORK (GenomeWeb) – NX Prenatal said today that it has entered a collaboration with Indiana University School of Medicine to further validate its early pregnancy biomarker panels that predict spontaneous preterm birth and to continue developing its biomarker panels for preeclampsia. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

  • Startup Cadex Genomics Raises $1.5M

  • All Breast Cancer Patients Should Receive Multigene Panel Tests, Surgeon Group Says

  • In Brief This Week: BioDirection, Quest Diagnostics, OncoCyte, and More

  • Jefferies Initiates Coverage of CareDx With Buy Rating

  • Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

  • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance

What's Popular?

In Business News
  1. SAW Diagnostics Wins Platform Development Funds for POC MDx Sample Prep System

  2. Karius Infectious Disease Dx Shows Promise, but Questions Remain on Clinical Indication

    Premium
  3. Jefferies Initiates Coverage of CareDx With Buy Rating

  4. Burning Rock Lands $126M in Series C Financing Round

  5. Geneoscopy Develops Colorectal Cancer Dx Using RNA Biomarkers, Taking Aim at Exact Sciences

    Premium

Sponsorships

  • About Us
  • Advertise
  • Contact
  • Jobs
  • Sitemap
Subscribe

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.